Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy?
Touw
Ivo P
IP
Bontenbal
Marijke
M
D000208:Acute Disease; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy; D017024:Chemotherapy, Adjuvant; D004195:Disease Models, Animal; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007951:Leukemia, Myeloid / Q000139:chemically induced* / Q000235:genetics*; D051379:Mice; D018345:Mice, Knockout; D009154:Mutation; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000235:genetics*; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications / Q000151:congenital; D016184:Receptors, Colony-Stimulating Factor / Q000235:genetics*
C517047:CSF3R protein, human; D016184:Receptors, Colony-Stimulating Factor; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor